NCT06747858 - Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Cystic FibrosisCFTR Gene Mutation

Interventions

BIOLOGICAL

ARCT-032

CFTR mRNA formulated in lipid nanoparticles

Trial Locations (11)

32803

ACTIVE_NOT_RECRUITING

Central Florida Pulmonary Group, Orlando

33021

RECRUITING

Joe DiMaggio Children's Hospital, Hollywood

37232

RECRUITING

Vanderbilt University, Nashville

60093

RECRUITING

The Cystic Fibrosis Institute, Northfield

63144

RECRUITING

Washington University, St Louis

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

78229

RECRUITING

UT Health, San Antonio

85724

RECRUITING

University of Arizona, Tucson

90027

RECRUITING

Children's Hospital of Los Angeles, Los Angeles

98105

RECRUITING

Seattle Children's Hospital, Seattle

02115

RECRUITING

Boston Children's Hospital, Boston